# Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

> **NCT02250651** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 528 (actual)

## Conditions studied

- Glaucoma, Open-Angle
- Ocular Hypertension

## Interventions

- **DRUG:** Bimatoprost SR
- **OTHER:** Sham: Applicator Without Needle
- **DRUG:** Active Comparator: Timolol 0.5%
- **DRUG:** Timolol Vehicle (placebo)

## Key facts

- **NCT ID:** NCT02250651
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-15
- **Primary completion:** 2018-10-25
- **Final completion:** 2020-07-22
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2021-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02250651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02250651, "Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02250651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*